Homepage
Author:
Olema Oncology
Posted Date:
April 2, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology
April 2, 2026
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
Olema Oncology
March 17, 2026
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Olema Oncology
March 16, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology
March 3, 2026
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Olema Oncology
February 25, 2026
Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference
Olema Oncology
February 19, 2026
Olema Oncology to Participate in Upcoming Investor Conferences
Olema Oncology
February 7, 2026
Olema Oncology Announces Departure of Chief Operating and Financial Officer
Olema Oncology
January 30, 2026
